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A CLINICAL EXPERIENCE WITH FILACUL CAPSULE
  （1一 （2－TETRAHYDROFURYL） 一5－FLUOROURACIL）
           IN BLADDER TUmoR
Taka6 IKEucHi， Hajime OGAwA， Yoshio HiGAKi and Kazuo IMAMuRA
    From伽1）吻伽鋸Of Urology， Schoolげルfedicine， Shoωa Univer吻
             （Director： Prof， K lmamura）
  Filacul capsule was used to 25 cases of bladder tumor and the thcrapeutic effects；both anti－
tumor and recurrence－preventive effects were examined．
  Described below are the results of the study：
1） The therapy was recognized as effective in five of i 2 cases （41．70／，） for the anti－tumor effects and
 eleven of 13 cases （84．6C／o） fer recurrence－preventive effects．
2） The anti－tumor effects were recognized for primary tumor cases and found to be correlated with
 both grade and stage．
3） The recurrence－preventive effects， which were also good against primary tumor cases， were found
 to be correla亡ed wi亡h grade bu亡not wi亡h s亡age．
4） Good correlation was observed between the therapeutic efllcacy and the doses． Efficacy was
 observed ’in many of the cases dosed・more than 100 g．
5） Side eff．ects appeared in 480／， of the total cases and the administration was discontinued in 160／o．
































はGrade Iが6例， Gradc IIが5例， Grade IIIが
2例，浸潤度はStagc Aが11例， Stage BおよびC
が各1例である．


















    失したもの
 やや有効＝主腫瘍，娘腫瘍とも50％以下の縮


































































TUR  CA膀胱内・M 獣
道．C蠣胱内M・MMC・C綴内泓鰍
 一        MMC・CA膀胱内注入著効
盤霧車内泓MM・蠕駐 醐
MMC・CA膀胱内注入MMC・CA膀胱内注入有効
                   やや 一        CQ・CA膀胱内注入                   有効
畿．C鵬胱内tw， MMC・・me内泓鰍
池内・ほか：膀胱腫瘍・Filacul capsule










































Nα性 年齢 発生 悪性度 浸油度 総投与量（g） 投与前治療 併用治療 効果
1 ♂ 68 初 発 1
2 ♀ 66 初 発  H
3 ♀  62 再発（同） H
4 ♂ 72 初 発  皿
5♂68醗（異）1旺
6 ♂ 76 初 発
7 ♂ 69 初 発




9 ♀ 69 初 発  ■
10  ♀   87  初  発    1
11 ♂ 70 初 発 1
12♂82初発皿































































































とGrade Iが6／6（loo％）， Grade IIが3／4（75％），
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